{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:47:56Z","timestamp":1790171276830,"version":"4.1.0"},"reference-count":23,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T00:00:00Z","timestamp":1556841600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001794","name":"University of Queensland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Yellow fever virus (YFV) is endemic to tropical and subtropical areas in South America and Africa, and is currently a major public health threat in Brazil. Transfusion transmission of the yellow fever vaccine virus has been demonstrated, which is indicative of the potential for viral transfusion transmission. An approach to manage the potential YFV transfusion transmission risk is the use of pathogen inactivation (PI) technology systems, such as THERAFLEX MB\u2010Plasma and THERAFLEX UV\u2010Platelets (Macopharma). We aimed to investigate the efficacy of these PI technology systems to inactivate YFV in plasma or platelet concentrates (PCs).<\/jats:p><\/jats:sec><jats:sec><jats:title>STUDY DESIGN AND METHODS<\/jats:title><jats:p>YFV spiked plasma units were treated using THERAFLEX MB\u2010Plasma system (visible light doses: 20, 40, 60, and 120 [standard] J\/cm<jats:sup>2<\/jats:sup>) in the presence of methylene blue (approx. 0.8 \u03bcmol\/L) and spiked PCs were treated using THERAFLEX UV\u2010Platelets system (ultraviolet C doses: 0.05, 0.10, 0.15, and 0.20 [standard] J\/cm<jats:sup>2<\/jats:sup>). Samples were taken before the first and after each illumination dose and tested for residual virus using a modified plaque assay.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>YFV infectivity was reduced by an average of 4.77 log or greater in plasma treated with the THERAFLEX MB\u2010Plasma system and by 4.8 log or greater in PCs treated with THERAFLEX UV\u2010Platelets system.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Our study suggests the THERAFLEX MB\u2010Plasma and the THERAFLEX UV\u2010Platelets systems can efficiently inactivate YFV in plasma or PCs to a similar degree as that for other arboviruses. Given the reduction levels observed in this study, these PI technology systems could be an effective option for managing YFV transfusion\u2010transmission risk in plasma and PCs.<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.15332","type":"journal-article","created":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T15:48:52Z","timestamp":1556898532000},"page":"2223-2227","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Inactivation of yellow fever virus in plasma after treatment with methylene blue and visible light and in platelet concentrates following treatment with ultraviolet C light"],"prefix":"10.1111","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3446-8248","authenticated-orcid":false,"given":"Helen M.","family":"Faddy","sequence":"first","affiliation":[{"name":"Research and Development Australian Red Cross Blood Service  Brisbane Queensland Australia"},{"name":"School of Biomedical Sciences The University of Queensland  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse J.","family":"Fryk","sequence":"additional","affiliation":[{"name":"Research and Development Australian Red Cross Blood Service  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy A.","family":"Hall","sequence":"additional","affiliation":[{"name":"Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences The University of Queensland  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Young","sequence":"additional","affiliation":[{"name":"Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences The University of Queensland  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Reichenberg","sequence":"additional","affiliation":[{"name":"Macopharma International GmbH  Langen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Tolksdorf","sequence":"additional","affiliation":[{"name":"Macopharma International GmbH  Langen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chryslain","family":"Sumian","sequence":"additional","affiliation":[{"name":"Macopharma  Tourcoing France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Gravemann","sequence":"additional","affiliation":[{"name":"German Red Cross Blood Service NSTOB  Springe Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Seltsam","sequence":"additional","affiliation":[{"name":"German Red Cross Blood Service NSTOB  Springe Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denese C.","family":"Marks","sequence":"additional","affiliation":[{"name":"Research and Development Australian Red Cross Blood Service  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,5,3]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2009.01286.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30620-1"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.6606"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.7326\/M17-1337"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-3527(03)61007-9"},{"key":"e_1_2_8_7_1","unstructured":"Centers for Disease Control and Prevention [monograph on the internet]. [cited 2018 Mar 15]. Available from:https:\/\/wwwnc.cdc.gov\/travel\/notices\/alert\/yellow-fever-brazil."},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2016.04.025"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/905043"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2210.160875"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2012.08.015"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2007.10.009"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.4.4.553"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02111.x"},{"key":"e_1_2_8_15_1","first-page":"34","article-title":"Transfusion\u2010related transmission of yellow fever vaccine virus\u2013California, 2009","volume":"59","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02334.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000323845"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2012.03858.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13519"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14256"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13729"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1159\/000441830"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14652"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1159\/000323786"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftrf.15332","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.15332","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/trf.15332","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.15332","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T21:58:45Z","timestamp":1694296725000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.15332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,3]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1111\/trf.15332"],"URL":"https:\/\/doi.org\/10.1111\/trf.15332","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,3]]},"assertion":[{"value":"2018-05-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}